News AZ cues up broader use of Imfinzi in bladder cancer The results of the VOLGA trial have buoyed AstraZeneca's ambitious growth targets for PD-L1 inhibitor Imfinzi in bladder cancer.
News BMS signs $15.2bn R&D alliance with China's Hengrui Hengrui agrees a $15.2bn R&D alliance with BMS in oncology/haematology and immunology, less than a year after a similar $12bn deal with GSK.
News Partner's Bizengri is first drug for rare, aggressive cancer Partner's Bizengri has been approved for a rare form of bile duct cancer, two days after being awarded a national priority review voucher.
News CellCentric pockets $220m for blood cancer programme CellCentric has raised $220 million in a Series D financing that will help fund pivotal trials of p300/CBP inhibitor inobrodib in multiple myeloma.
News UK's Cytospire draws in $83m for new T-cell engager platform Cytospire was in the spotlight this morning after announcing an oversubscribed Series A to fund a new form of T-cell engager (TCE) for cancer.
News 'Seismic shift' as obesity overtakes cancer for R&D returns For the first time in its 16-year history, Deloitte's annual report on pharma R&D returns sees obesity replace cancer as the largest driver.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.